Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

NCT06906081 is registered in ClinicalTrials.gov with Peter Rossing as lead sponsor.

NCT NCT06906081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06906081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
Lead sponsor
Peter Rossing
Phase
Phase 2
Overall status
Recruiting
Start date
May 2, 2025
Completion date
January 31, 2028
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular autonomic neuropathy, diabetic neuropathies, type 2 diabetes